Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03217110 · ClinicalTrials.gov registry record · NA

Cerebellar Stimulation and Cognitive Control

A NA study of Depression and Schizophrenia, sponsored by Krystal Parker, PhD.

Recruiting
Registry status
NA
Development phase
200
Enrollment target
1
Study location

NCT03217110 is a NA study of Depression and Schizophrenia that is actively recruiting participants, run by Krystal Parker, PhD. The registered enrollment target is 200 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03217110, a NA study of Depression and Schizophrenia, is actively recruiting participants, sponsored by Krystal Parker, PhD.

RECRUITING
Registry status
NA
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to examine whether cerebellar stimulation can be used to improve cognitive deficits and mood in patients with schizophrenia, autism, bipolar disorder, Parkinson's disease, and major depression.

Interventions

  • DEVICE Repetitive Transcranial Magnetic Stimulation (rTMS)
  • DEVICE Sham Repetitive Transcranial Magnetic Stimulation (rTMS)

Study Locations (1)

Iowa

  • University of Iowa - Iowa City

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2017-11-30
Est. Completion 2028-12-01
Phase NA

Sponsor

Krystal Parker, PhD

1 total trials

What the Registry Record Tells You About NCT03217110

The ClinicalTrials.gov registry entry for NCT03217110 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (75% lower). The listed sponsor is Krystal Parker, PhD, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Repetitive Transcranial Magnetic Stimulation (rTMS) is the first listed.

NCT03217110 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.

Frequently Asked Questions

What is clinical trial NCT03217110 about?

NCT03217110 is a clinical study titled "Cerebellar Stimulation and Cognitive Control". The purpose of this study is to examine whether cerebellar stimulation can be used to improve cognitive deficits and mood in patients with schizophrenia, autism, bipolar disorder, Parkinson's disease, and major depression.

What is the current status of trial NCT03217110?

This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2017-11-30. Estimated completion is 2028-12-01.

What conditions does trial NCT03217110 study?

This clinical trial studies the following conditions: Depression, Schizophrenia, Parkinson Disease, Autism Spectrum Disorder, Bipolar Disorder.

What interventions are being tested in trial NCT03217110?

The interventions under investigation include: Repetitive Transcranial Magnetic Stimulation (rTMS) (DEVICE), Sham Repetitive Transcranial Magnetic Stimulation (rTMS) (DEVICE).

Who is sponsoring clinical trial NCT03217110?

This trial is sponsored by Krystal Parker, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03217110 being conducted?

This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.